博碩士論文 101233006 詳細資訊




以作者查詢圖書館館藏 以作者查詢臺灣博碩士 以作者查詢全國書目 勘誤回報 、線上人數:24 、訪客IP:35.172.217.40
姓名 林君潔(Jun-jie Lin)  查詢紙本館藏   畢業系所 系統生物與生物資訊研究所
論文名稱 中草藥BP004誘導管腔A型乳腺癌細胞凋亡
(BP004, a Traditional Chinese Medicine, induces apoptosis in human luminal A breast cancer cell lines)
相關論文
★ 藉由微陣列基因晶片以探討中草藥BP011w對於抑制肺腺癌細胞株爬行及轉移之機制★ 鑑別可應用在病理與臨床之肺腺癌與鱗狀上皮細胞肺癌的生物標記
★ 中國傳統醫藥蒙古黃耆在HCT116結腸癌細胞體外和體內實驗呈現腫瘤抑制作用★ 泰莫西芬與BP012W乙醇分離物之協同作用造成強化管狀A型乳腺癌細胞凋亡影響
★ 揭示CEP55基因在大腸直腸癌轉移中所扮演的角色★ BP016W-新型食道鱗狀上皮細胞癌候選藥物
★ 傳統中藥複方FY001W是三陰性乳腺癌新型的候選藥物★ BP023W在頭頸癌中的細胞毒性與調控機制
★ 藉由L1000?表達圖譜數據來解釋中醫分類方法中的屬性和歸經★ Solasodine,BP010W成份之一,抑制肺癌的遷移和侵襲能力
★ 蒙古黃耆對大腸癌影響並降低miR-29a的表現量之研究
檔案 [Endnote RIS 格式]    [Bibtex 格式]    [相關文章]   [文章引用]   [完整記錄]   [館藏目錄]   [檢視]  [下載]
  1. 本電子論文使用權限為同意立即開放。
  2. 已達開放權限電子全文僅授權使用者為學術研究之目的,進行個人非營利性質之檢索、閱讀、列印。
  3. 請遵守中華民國著作權法之相關規定,切勿任意重製、散佈、改作、轉貼、播送,以免觸法。

摘要(中) 乳癌發生率及死亡率逐年攀升,但是主流醫學並沒有辦法延長患者生命。雖然多本中醫古籍記載具有清熱解毒、活血化瘀 等特性的中藥能緩解癌症病徵,主流醫學還沒有對它們的療效做科學驗證。我們利用高通量細胞學藥物篩選系統從約60種此類中草藥篩選出蒲公英萃取物BP004為候選治療藥物,並利用多種量化方法證實BP004對乳癌細胞的確有抑制生長及毒殺的效果。首先我們使用細胞存活率試驗證明BP004能抑制基底A型乳癌細胞MCF-7細胞生長。其對基底A型乳癌細胞MCF-7的50% 生長抑制所需濃度(IC50)為550μg/ml; 對基底A型乳癌細胞T47D為700μg/ml。對三陰性乳癌細胞MDA-MB-231、her-2/neu陽性乳癌細胞MDA-MB-453及正常乳腺上皮細胞 H184B5F5/M10無生長抑制的反應。我們接著使用流式細胞儀觀察上列細胞株對BP004處理的反應,發現基底A型乳癌細胞MCF-7會發生細胞凋亡。並使用西方墨點法量化經不同濃度BP004處理後各細胞株蛋白質的表現量,並發現基底A型乳癌細胞MCF-7的BAX, CASP-7, FAS等蛋白質表現量在BP004濃度為200-400 μg/ml BCL-2時上升,其BCL-2 蛋白質則隨之下降,表示BP004能使細胞走向內部凋亡。最後我們透過全基因體表現量分析,證實BP004除了向上調節基底A型乳癌細胞MCF-7細胞凋亡。此外,我們還發現有細胞週期及細胞外來刺激反應等功能。以上結果顯示BP004有潛力成為基底A型乳癌細胞之乳癌新藥。未來我們會強化過去的研究外,也會繼續進行動物層次研究,對於BP004是否可當作抗癌藥物需要再作更深入的評估其抗癌的功效。我們希望藉由臨床樣本的數據,以高通量微陣列晶片的技術利用系統生物學來整合基因調控元素及蛋白質交互作用間複雜的關係為藥物BP004的治療建立出可鑑別的乳癌分子標記。
摘要(英) Breast cancer incidence and mortality rates haves increased over the years, but due to limitation of current medicines, there were no effective way extending the lives of patients. Although many Chinese ancient books had recorded the benefits of Chinese medicine in terms of cancer treatments by alleviating fever, de-toxication and, eliminating the blood flow by promoting blood circulation, the mainstream medicines still haves not yet approve scientifically their efficacies and use. In this study, we used high-throughput drug screening cytology system (High-throughput Drug Screening System Cytology, HT-DSSC) to screen 60 herbal extracts, and BP004 (The dandelion extract) was the candidate for our study. BP004 was found to inhibit the growth of luminal-A breast cancer cell line MCF-7 by inducing cell apoptosis; however, none of the triple-negative breast cancer cell lines such as MDA-MB 231, HER2-positive breast cancer cell lines MDA-MB-453 and normal mammary epithelial cell H184B5F5/M10 were effected. The extrinsic and intrinsic apoptosis pathways were examined by Western blot. We found that BAX, CASP-7, and FAS proteins were increased in expression while, BCL-2 was decreased expression, indicating cells undergo apoptosis through the intrinsic pathway. Finally, using microarray analysis, genes involved with "cell cycle" and "cellular response to stimulus were also identified". These results indicated that BP004 has is the potential adjuvant drug in the treatment of breast cancer cells. In the future, we will conduct animal experiments, to further confirm the effectiveness of BP004 in the treatment of breast cancer. We use of the technology for high-throughput microarray systems biology to integrate the complex relationships between elements of gene regulation and protein interactions for drug BP004 establish a molecular markers for breast cancer classification.
關鍵字(中) ★ 乳癌
★ 蒲公英
★ 中草藥
★ 基底A型乳癌
★ 細胞凋亡
關鍵字(英) ★ Breast cancer
★ Dandelion
★ Traditional Chinese medicine
★ Luminal A
★ Apoptosis
論文目次 Table of contents
中文摘要 i
Abstract ii
誌謝 iii
Table of contents iv
List of Tables vi
List of figures vii
List of supplements Tables viii
List of supplements figures ix
1. Introduction 1
1-1 Breast cancer 1
1-1-1. Pathology and clinical stage classification of breast cancer 2
1-1-2. Molecular genetics of breast cancer and targeted therapy 3
2. Materials and Method 6
2-1. Chemicals and media 6
2-1-1. Cell lines 6
2-1-2. Research reagents and antibodies 6
2-2. Traditional Chinese Medicine (TCM) experiment 8
2-2-1. High-Throughput Drug Screening System Cytology 8
2-2-2. Preparation of BP004 8
2-2-3. Cell culture and cell treatment 9
2-2-4. Cell proliferation assay 10
2-2-5. Analysis of apoptosis by flow cytometry assay 10
2-2-6. Preparation of protein extracts 11
2-2-7. Western blot assay 11
2-2-8. Preparation of RNA extracts 12
2-2-9. Microarray hybridization 12
2-3. Data analysis 13
2-3-1. Data quality control 14
2-3-2. Differential expression analysis 15
2-3-3. Function and pathway analysis 15
2-3-4. Drug prediction 15
3. Results 16
3-1. High-throughput Drug Screening System Cytology 16
3-1-1. In vitro cytotoxicity study by alamar blue assay 20
3-1-2. Apoptosis analysis by flow cytometry 21
3-1-3. Expression of apoptosis-related proteins was analyzed by western blot 21
3-2. Bioinformatics analysis 25
3-2-1. Genome-wide expression profiling 25
3-2-2. Data quality assurance 25
3-2-3. Differential expression analysis 30
3-2-4. Function and pathway analysis 30
4. Summary and discussion 43
5. Reference 45
6. Supplements 48
7. Appendix 61
參考文獻 1. Siegel Rebecca, Ward Elizabeth, Brawley Otis, Jemal Ahmedin (2011). "Cancer statistics, 2011". CA: a cancer journal for clinicians 61: 212-236.
2. Ferlay Jacques, Shin Hai‐Rim, Bray Freddie, Forman David, Mathers Colin, et al. (2010). "Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008". International journal of cancer 127: 2893-2917.
3. Society American Cancer (2014). "Cancer Facts & Figures 2014".
4. Institute. National Cancer. SEER Stat Fact Sheets: Breast Cancer. 2011; Available from: http://seer.cancer.gov/statfacts/html/breast.html.
5. Siegel Rebecca, Ma Jiemin, Zou Zhaohui, Jemal Ahmedin (2014). "Cancer statistics, 2014". CA: a cancer journal for clinicians 64: 9-29.
6. Hutchinson Lisa (2010). "Breast cancer: challenges, controversies, breakthroughs". Nature Reviews Clinical Oncology 7: 669-670.
7. 衛生福利部. 民國101年主要死因分析. 2014; Available from: http://www.mohw.gov.tw/cht/DOS/Statistic.aspx?f_list_no=312&fod_list_no=2747.
8. 趙大中. 台灣女性近10年來乳癌的發生史為何?. 2009; Available from: http://cisc.twbbs.org/lib/addon.php?act=post&id=1787.
9. Fox Maurice S (1979). "On the diagnosis and treatment of breast cancer". Jama 241: 489-494.
10. Institute. National Cancer. Breast Cancer. 2014; Available from: http://www.cancer.gov/cancertopics/types/breast/.
11. Encyclopedia. A.D.A.M. Medical. Breast cancer. 2012; Available from: http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0001911/.
12. Nielsen Torsten O, Hsu Forrest D, Jensen Kristin, Cheang Maggie, Karaca Gamze, et al. (2004). "Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma". Clinical Cancer Research 10: 5367-5374.
13. Cheang Maggie CU, Chia Stephen K, Voduc David, Gao Dongxia, Leung Samuel, et al. (2009). "Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer". Journal of the National Cancer Institute.
14. Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thürlimann B, et al. (2011). "Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011". Annals of oncology: mdr304.
15. Sotiriou Christos, Pusztai Lajos (2009). "Gene-expression signatures in breast cancer". New England Journal of Medicine 360: 790-800.
16. van′t Veer Laura J, Dai Hongyue, Van De Vijver Marc J, He Yudong D, Hart Augustinus AM, et al. (2002). "Gene expression profiling predicts clinical outcome of breast cancer". nature 415: 530-536.
17. Hu Zhiyuan, Fan Cheng, Oh Daniel S, Marron JS, He Xiaping, et al. (2006). "The molecular portraits of breast tumors are conserved across microarray platforms". BMC genomics 7: 96.
18. Perou Charles M, Sørlie Therese, Eisen Michael B, van de Rijn Matt, Jeffrey Stefanie S, et al. (2000). "Molecular portraits of human breast tumours". Nature 406: 747-752.
19. Sørlie Therese, Perou Charles M, Tibshirani Robert, Aas Turid, Geisler Stephanie, et al. (2001). "Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications". Proceedings of the National Academy of Sciences 98: 10869-10874.
20. Sørlie Therese, Tibshirani Robert, Parker Joel, Hastie Trevor, Marron JS, et al. (2003). "Repeated observation of breast tumor subtypes in independent gene expression data sets". Proceedings of the National Academy of Sciences 100: 8418-8423.
21. Sotiriou Christos, Neo Soek-Ying, McShane Lisa M, Korn Edward L, Long Philip M, et al. (2003). "Breast cancer classification and prognosis based on gene expression profiles from a population-based study". Proceedings of the National Academy of Sciences 100: 10393-10398.
22. Goldhirsch Aron, Glick John H, Gelber Richard D, Coates Alan S, Senn Hans-Jörg (2001). "Meeting highlights: international consensus panel on the treatment of primary breast cancer". Journal of Clinical Oncology 19: 3817-3827.
23. Holliday Deborah L, Speirs Valerie (2011). "Choosing the right cell line for breast cancer research". Breast Cancer Res 13: 215.
24. Chen Ming Hui, Chuang Michael L, Bornstein Bruce A, Gelman Rebecca, Harris Jay R, et al. (1997). "Impact of respiratory maneuvers on cardiac volume within left-breast radiation portals". Circulation 96: 3269-3272.
25. Huang Da Wei, Sherman Brad T, Lempicki Richard A (2009). "Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists". Nucleic acids research 37: 1-13.
26. Da Wei Huang Brad T Sherman, Lempicki Richard A (2008). "Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources". Nature protocols 4: 44-57.
27. 中國醫藥導報. 中醫多法 治療腫瘤. 2011.4; Available from: http://www.chnews2010.com/cmr/2011-4.pdf.
28. Wu Hsing L, Hsu Chen Y, Liu Wen H, Yung Benjamin YM (1999). "Berberine‐induced apoptosis of human leukemia HL‐60 cells is associated with down‐regulation of nucleophosmin/B23 and telomerase activity". International journal of cancer 81: 923-929.
29. Hengartner Michael O (2000). "The biochemistry of apoptosis". Nature 407: 770-776.
30. Efferth Thomas, Li Paul CH, Konkimalla Venkata S Badireenath, Kaina Bernd (2007). "From traditional Chinese medicine to rational cancer therapy". Trends in molecular medicine 13: 353-361.
31. Cohen Isaac, Tagliaferri Mary, Tripathy Debu. Traditional Chinese medicine in the treatment of breast cancer. in Seminars in oncology. 2002. Elsevier.
32. Wang Sun-Chong (2013). Western Biomedicine and Eastern Therapeutics: An Integrative Strategy for Personalized and Preventive Healthcare. 2013: World Scientific Publishing Company.
指導教授 蘇立仁(Li-Jen Su) 審核日期 2014-8-27
推文 facebook   plurk   twitter   funp   google   live   udn   HD   myshare   reddit   netvibes   friend   youpush   delicious   baidu   
網路書籤 Google bookmarks   del.icio.us   hemidemi   myshare   

若有論文相關問題,請聯絡國立中央大學圖書館推廣服務組 TEL:(03)422-7151轉57407,或E-mail聯絡  - 隱私權政策聲明